Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3ζ recombinant gene

References

• Maloney D G, Grillo-L'opez A J, White C A, Bodkin D, Schilder R J, Neidhart J A, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Zasadny K R, Francis I R, Fenner M C, Ross C W, Milik A W, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974–1981
   PubMed Web of Science ®Google Scholar
• Press O W, Eary J E, Appelbaum F R, Martin P J, Nelp W B, Glenn S, et al. Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 336–340
   PubMed Web of Science ®Google Scholar
• Knox S J, Goris M L, Trisler K, Negrin R, Davis T, Liles T, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996; 2: 457–470
   PubMed Web of Science ®Google Scholar
• Schirrmann T, Pecher G. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk Res 2005; 29: 301–306
   PubMed Web of Science ®Google Scholar
• Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994; 91: 4318–4322
   PubMed Web of Science ®Google Scholar
• Hwu P, Yang J C, Cowherd R, Treisman J, Shafer G E, Eshhar Z, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995; 55: 3369–3373
   PubMed Web of Science ®Google Scholar
• Weijtens M E, Willemsen R A, Valerio D, Stam K, Bolhuis R L. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 1996; 157: 836–843
   PubMed Web of Science ®Google Scholar
• Wang J, Press O W, Lindgren C G, Greenberg P, Riddell S, Qian X, et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther 2004; 9: 577–586
   PubMed Web of Science ®Google Scholar
• Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 2001; 167: 6123–6131
   PubMed Web of Science ®Google Scholar
• Shan D, Press O W, Tsu T T, Hayden M S, Ledbetter J A. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. J Immunol 1999; 162: 6589–6595
   PubMed Web of Science ®Google Scholar
• Hu Y-X,Yu K. Research advance in malignant tumors and zeta chains of T and NK cells. Foreign medical sciences oncology section 2004; 34: 803–806
   Google Scholar
• Moeller M, Haynes N M, Trapani J A, Teng M W, Jackson J T, Tanner J E, et al. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther 2004; 11: 371–379
   PubMed Web of Science ®Google Scholar
• Cooper L J, Topp M S, Serrano L M, Gonzalez S, Chang W C, Naranjo A, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft–versus–B-lineage leukemia effect. Blood 2003; 101: 1637–1644
   PubMed Web of Science ®Google Scholar
• Jensen M C, Cooper L J, Wu A M, Forman S J, Raubitschek A. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 2003; 5: 131–138
   PubMed Web of Science ®Google Scholar
• Hombach A, Sircar R, Heuser C, Tillmann T, Diehl V, Kruis W, et al. Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signaling chains. Int J Mol Med 1998; 2: 99–103
   PubMed Web of Science ®Google Scholar
• Patel S D, Ge Y, Moskalenko M, McArthur J G. Anti-tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions. J Immunother 2000; 23: 661–668
   PubMed Web of Science ®Google Scholar
• Maher J, Brentjens R J, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 2002; 20: 70–75
   PubMed Web of Science ®Google Scholar
• Losch F O, Muller R, Mutschler B, Neri D, Natali P G, Reth M, et al. Activation of T cells via tumor antigen specific chimeric receptors: the role of the intracellular signaling domain. Int J Cancer 2003; 103: 399–407
   PubMed Web of Science ®Google Scholar
• Gilham D E, O'Neil A, Hughes C, Guest R D, Kirillova N, Lehane M, et al. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3 zeta-based chimeric immune receptors. J Immunother 2002; 25: 139–151
   PubMed Web of Science ®Google Scholar
• Ren-Heidenreich L, Mordini R, Hayman G T, Siebenlist R, LeFever A. Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis. Cancer Immunol Immunother 2002; 51: 417–423
   PubMed Web of Science ®Google Scholar
• Morel P A, Oriss T B. Crossregulation between Th1 and Th2 cells. Crit Rev Immunol 1998; 18: 275–303
   PubMed Web of Science ®Google Scholar
• Mueller D L, Seiffert S, Fang W, Behrens T W. Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells: a model for the long-term survival of memory cells. J Immunol 1996; 156: 1764–1771
   PubMed Web of Science ®Google Scholar
• Mor F, Cohen I R. IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis: correlation with induction of Bcl-2. J Immunol 1996; 156: 515–522
   PubMed Web of Science ®Google Scholar
• Radvanyi L G, Shi Y, Vaziri H, Sharma A, Dhala R, Mills G B, et al. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol 1996; 156: 1788–1798
   PubMed Web of Science ®Google Scholar